SOUTH SAN FRANCISCO, Calif.,
March. 4, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ:
STRO), a clinical-stage drug discovery, development and
manufacturing company focused on the application of precise protein
engineering and rational design to create next-generation oncology
therapeutics, today announced proof of concept data for a next
generation dual conjugated combination immunostimulatory antibody
drug conjugate (IADC). This breakthrough concept of a tumor
targeting monotherapy, which simultaneously attacks tumor cells
while stimulating a patient's own immune system, has the promise of
generating long-term immunity.
The IADC was generated with Sutro's proprietary and integrated
cell-free protein synthesis platform XpressCF® and site-specific
conjugation platform XpressCF+™. It enables precise tumor targeting
with a combination of a novel toll-like receptor (TLR) agonist and
a traditional antibody drug conjugate warhead.
"This is a next-generation approach that utilizes Sutro's
technology to take ADCs into the future, potentially enabling a
sustained and adaptive anti-tumor immune response," said Sutro's
Chief Scientific Officer, Trevor Hallam, PhD. "Here we
have showcased how a targeted cytotoxin can stimulate immunogenic
cell death and provide a synergistic stimulation of immune system
memory responses when paired together with TLR agonists. Generating
adaptive and protective immunity from the patient's own tumors
in situ, especially in an off-the-shelf product, is a
significant leap forward in targeted oncology therapeutics."
Dr. Hallam is a featured speaker at the 10th Annual World ADC
London and delivering a plenary presentation titled "Targeted
Immunostimulants; A Promising Approach to In Situ Immunisation."
The slides will be accessible through the Clinical/Scientific
Presentation and Publication Highlights page of the News section of
the company's website at www.sutrobio.com.
About Sutro Biopharma
Sutro Biopharma, Inc., located
in South San Francisco, is a
clinical-stage drug discovery, development and manufacturing
company. Using precise protein engineering and rational design,
Sutro is advancing next-generation oncology therapeutics.
Sutro's proprietary and integrated cell-free protein synthesis
platform XpressCF® and site-specific conjugation platform,
XpressCF+™, led to the discovery of STRO-001 and STRO-002, Sutro's
first two internally-developed ADCs. STRO-001 is a CD74-targeting
ADC currently being investigated in a Phase I clinical trial of
patients with advanced B-cell malignancies, including multiple
myeloma and non-Hodgkin lymphoma. STRO-001 was granted Orphan Drug
Designation by the FDA for multiple myeloma in October 2018. STRO-002 is a folate receptor alpha
(FolRα)-targeting ADC, currently being investigated in a Phase I
clinical trial of patients with ovarian and endometrial cancers.
This is the second product candidate to be evaluated in clinical
trials resulting from Sutro's XpressCF® and XpressCF+™
technology platforms. A third program, CC-99712 (BCMA-targeting
ADC), which is part of Sutro's collaboration with Bristol-Myers
Squibb (formerly Celgene Corporation), recently began enrolling
patients for its Phase I clinical trial of patients with multiple
myeloma. Sutro's proprietary technology was responsible for the
discovery and manufacturing of CC-99712, for which Bristol-Myers
Squibb has worldwide development and commercialization rights.
Sutro is entitled to development and regulatory milestone payments
and tiered royalties from Bristol-Myers Squibb for this BCMA
ADC.
Sutro is dedicated to transforming the lives of cancer patients
by creating medicines with improved therapeutic profiles for areas
of unmet need.
To date, Sutro has designed cytokine-based immuno-oncology
therapies, ADCs, vaccines and bispecific antibodies primarily
directed at clinically-validated targets for which the current
standard of care is suboptimal.
Sutro's platform allows it to accelerate discovery and
development of potential first-in-class and best-in-class molecules
through rapid and systematic evaluation of protein
structure-activity relationships to create optimized homogeneous
product candidates.
In addition to developing its own oncology pipeline, Sutro is
collaborating with select pharmaceutical and biotech companies to
discover and develop novel, next-generation therapeutics. As the
pace of clinical development accelerates, Sutro and its partners
are developing therapeutics designed to more efficiently kill
tumors without harming healthy cells.
Additional multimedia content from Sutro regarding STRO-001 and
STRO-002 can be found here and here.
Follow Sutro on Twitter, @Sutrobio, and at www.sutrobio.com to
learn more about our passion for changing the future of
oncology.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, anticipated preclinical and clinical
development activities, potential benefits of the company's product
candidates and platform and potential market opportunities for the
company's product candidates. All statements other than statements
of historical fact are statements that could be deemed
forward-looking statements. Although the company believes that the
expectations reflected in such forward-looking statements are
reasonable, the company cannot guarantee future events, results,
actions, levels of activity, performance or achievements, and the
timing and results of biotechnology development and potential
regulatory approval is inherently uncertain. Forward-looking
statements are subject to risks and uncertainties that may cause
the company's actual activities or results to differ significantly
from those expressed in any forward-looking statement, including
risks and uncertainties related to the company's ability to advance
its product candidates, the receipt and timing of potential
regulatory designations, approvals and commercialization of product
candidates, the Company's ability to maintain and recognize the
benefits of certain designations received by product candidates,
the timing and results of preclinical and clinical trials, the
company's ability to fund development activities and achieve
development goals, the company's ability to protect intellectual
property, and the Company's commercial collaborations with third
parties and other risks and uncertainties described under the
heading "Risk Factors" in documents the company files from time to
time with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date of this press
release, and the company undertakes no obligation to revise or
update any forward-looking statements to reflect events or
circumstances after the date hereof.
Investor Contacts
John
Graziano
Solebury Trout
+1 646-378-2942
jgraziano@soleburytrout.com
Xuan Yang
Solebury Trout
+1 646-378-2975
xyang@soleburytrout.com
Media Contacts
David
Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com
Travis Kruse
Russo Partners
(212) 845-4272
travis.kruse@russopartnersllc.com
View original
content:http://www.prnewswire.com/news-releases/sutro-biopharma-to-present-innovative-cancer-therapy-approach-using-precise-tumor-targeted-immunostimulants-at-world-adc-london-301013866.html
SOURCE Sutro Biopharma